logo-loader
viewCapricor Therapeutics

Capricor Therapeutics working on drug to treat a rare disorder DMD

Capricor Therapeutics (NASDAQ:CAPR) CFO AJ Bergmann joined Steve Darling and Proactive investors in California to talk about their drug for treating a rare childhood disease called Duchenne muscular dystrophy. That drug is entering Phase two of testing.

Bergmann also gave Proactive details on another drug they are working on to deal with Inflammatory and Fibriotic disorders.

Quick facts: Capricor Therapeutics

Price: 1.33 USD

NASDAQ:CAPR
Market: NASDAQ
Market Cap: $6.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Empower Clinics looking to attack opioid crisis with...

Empower Clinics (CSE:CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley joined Steve Darling from Proactive in Toronto to discuss the company creating a division focussing on psilocybin and psychedelics aka magic mushrooms. McAuley telling Proactive how key this may become considering the...

6 hours, 39 minutes ago

2 min read